This site uses cookies to ensure the best viewing experience for our readers.
Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen

Brief

Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen

The two companies will collaborate on the research of a “therapeutic area of mutual interest”

CTech | 13:25  24.04.2019
Nasdaq-listed UroGen Pharma Ltd. has announced a research agreement with Beerse, Belgium-headquartered Janssen Research & Development LLC, a subsidiary of Johnson & Johnson. The two companies have agreed to conduct “an early-stage feasibility evaluation in a therapeutic area of mutual interest.” The companies did not disclose the financial terms of the agreement.

Founded in 2004 under the name TheraCoat Ltd., Israel-based UroGen develops a gel for the sustained release of drugs in the field of urology. The company’s chairman of the board is Arie Belldegrun, the founder of cancer treatment company Kite Pharma for which Gilead Sciences Inc. paid $11.9 billion in 2017.

Nasdaq. Photo: Shutterstock Nasdaq. Photo: Shutterstock Nasdaq. Photo: Shutterstock

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS